[go: up one dir, main page]

MX2023010313A - Formulación y métodos de gliburida de baja sorción. - Google Patents

Formulación y métodos de gliburida de baja sorción.

Info

Publication number
MX2023010313A
MX2023010313A MX2023010313A MX2023010313A MX2023010313A MX 2023010313 A MX2023010313 A MX 2023010313A MX 2023010313 A MX2023010313 A MX 2023010313A MX 2023010313 A MX2023010313 A MX 2023010313A MX 2023010313 A MX2023010313 A MX 2023010313A
Authority
MX
Mexico
Prior art keywords
glyburide
methods
formulation
delivering
low sorption
Prior art date
Application number
MX2023010313A
Other languages
English (en)
Inventor
Yiqing Lin
Kenny K Tran
Deirdre Lowe
Rupa Rishikesh Sawant
Haihong Chen
Original Assignee
Biogen Chesapeake Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Chesapeake Llc filed Critical Biogen Chesapeake Llc
Publication of MX2023010313A publication Critical patent/MX2023010313A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/58—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/59—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of rings other than six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Métodos y formulaciones para minimizar o evitar la sorción de gliburida en las superficies de los tubos de suministro, filtros, bolsas y otros recipientes y materiales, almacenando y suministrando así un producto más estable, suministrando una dosis predecible y precisa de la gliburida, al tiempo que minimiza las impurezas, evita el desperdicio de medicamentos, reduce los costos y reduce significativamente la cantidad de solución de dosificación (generalmente solución salina o solución de Ringer) que se debe infundir al paciente.
MX2023010313A 2021-03-04 2022-03-04 Formulación y métodos de gliburida de baja sorción. MX2023010313A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163156533P 2021-03-04 2021-03-04
PCT/US2022/018821 WO2022187567A2 (en) 2021-03-04 2022-03-04 Low-sorbing glyburide formulation and methods

Publications (1)

Publication Number Publication Date
MX2023010313A true MX2023010313A (es) 2023-11-24

Family

ID=80930067

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010313A MX2023010313A (es) 2021-03-04 2022-03-04 Formulación y métodos de gliburida de baja sorción.

Country Status (11)

Country Link
US (4) US20220280537A1 (es)
EP (1) EP4301337A2 (es)
JP (1) JP2024512310A (es)
KR (1) KR20230165778A (es)
CN (1) CN117320727A (es)
AR (1) AR125033A1 (es)
CA (1) CA3210407A1 (es)
MX (1) MX2023010313A (es)
TW (1) TW202302117A (es)
UY (1) UY39658A (es)
WO (1) WO2022187567A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025212189A1 (en) 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema using a sur1-trpm4 channel inhibitor
WO2025212154A1 (en) 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
WO2025212155A1 (en) 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke with large vessel occlusion using a sur1-trpm4 channel inhibitor

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1269578B (it) * 1994-04-22 1997-04-08 Chiesi Farma Spa Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
US20030175349A1 (en) * 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
EP1765379A4 (en) 2004-06-17 2009-05-27 Transform Pharmaceuticals Inc PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS AND RELEVANT USE METHOD
EP1957028B1 (en) 2005-10-30 2017-06-07 Medimop Medical Projects Ltd. Needleless additive control valve
WO2008046014A1 (en) 2006-10-12 2008-04-17 Remedy Pharmaceuticals, Inc. Treatment of alzheimer's disease using compounds that reduce the activity of non-selective ca++- activated atp-sensitive cation channels regulated by sur1 receptors
EP2868315B1 (en) * 2007-12-04 2017-05-31 Remedy Pharmaceuticals, Inc. Improved formulations and methods for lyophilization and lyophilates provided thereby
US20110034560A1 (en) * 2008-01-29 2011-02-10 Sven Jacobson Liquid formulations of compounds active at sulfonylurea receptors
FR2987268B1 (fr) 2012-02-28 2014-07-11 Ammtek Formulations liquides de sulfamides hypoglycemiants
US10688295B2 (en) 2013-08-07 2020-06-23 West Pharma. Services IL, Ltd. Liquid transfer devices for use with infusion liquid containers
WO2016138473A1 (en) * 2015-02-26 2016-09-01 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inflammasome activation in myelodysplastic syndromes
CN105878194A (zh) 2016-06-07 2016-08-24 沈阳药科大学 一种格列本脲纳米结晶制剂及其制备方法
CN108210501B (zh) * 2016-12-14 2019-03-08 中国人民解放军军事医学科学院毒物药物研究所 一种磺酰脲类药物的注射用药物组合物及其制备方法
CN108553428A (zh) 2018-05-29 2018-09-21 昆药集团股份有限公司 格列本脲制剂及其制备方法

Also Published As

Publication number Publication date
AR125033A1 (es) 2023-05-31
TW202302117A (zh) 2023-01-16
CA3210407A1 (en) 2022-09-09
WO2022187567A3 (en) 2022-10-20
US20220280537A1 (en) 2022-09-08
US20250262227A1 (en) 2025-08-21
US20260021118A1 (en) 2026-01-22
EP4301337A2 (en) 2024-01-10
JP2024512310A (ja) 2024-03-19
KR20230165778A (ko) 2023-12-05
WO2022187567A2 (en) 2022-09-09
US20240285654A1 (en) 2024-08-29
UY39658A (es) 2022-09-30
US12496306B2 (en) 2025-12-16
CN117320727A (zh) 2023-12-29

Similar Documents

Publication Publication Date Title
MX2023010313A (es) Formulación y métodos de gliburida de baja sorción.
WO2014169081A3 (en) Methods and devices for point of use mixing of pharmaceutical formulations
AR130238A2 (es) Método para reducir la cantidad del producto de degradación dp3 durante la vida de estante de una composición farmacéutica en solución para aerosol y uso de un envase de aerosol asociado
MX2024010767A (es) Kit, formulacion y metodos de gliburida de baja sorcion.
EP3871708A3 (en) Wearable drug delivery system comprising a prefilled cartridge
HRP20191924T1 (hr) Postupci i sastavi za isporuku iduronat-2-sulfataze u cns
AU2014202862C1 (en) Implantable therapeutic device
BR112014008551A2 (pt) conjunto de válvulas para uso com recipiente de líquido e frasco de medicamento
PE20160681A1 (es) Formulacion de premezcla de dexmedetomidina
PH12013500477A1 (en) Aqueous drug delivery system comprising off-flavor masking agent
AR080586A1 (es) Tapa con filtro para jeringa y metodo para utilizarla para la adminstracion de una dosis de un medicamento
MX335944B (es) Composiciones que comprenden sulfato de salbutamol.
HRP20211734T1 (hr) Dozni oblici dugodjelujućeg hormona rasta
WO2012052853A3 (en) Oral dosing device for administration of medication
JP1736178S (ja) 薬物供給システム
JP1745013S (ja) 薬物供給システム
MX2018000259A (es) Dispositivo de suministro de un solo uso prellenado con un agente reconstituible.
EP4368175A3 (en) Perfusion dosage form
MX370890B (es) Composición que comprende sulfato de salbutamol.
MX2017008000A (es) Sistema de inyeccion de un solo uso.
JP2013518051A5 (es)
MX2018000258A (es) Dispositivo de suministro de un solo uso.
TN2009000088A1 (en) Packaging system for pharmaceutical compositions and kit for intravenous administration
HRP20201388T1 (hr) Režimi i postupci liječenja multiple skleroze uporabom ofatumumaba
RU2015119223A (ru) Система дозированного распределения